We are international
Donate
publications TEXT SIZE   


December 2000 Volume 4, Issue 2:
IMF Hosts WAM 2000
WAM 2000 Faculty: Dr. Morie Gertz Dr. Bart Barlogie Dr. James R. Berenson Dr. Raymond Alexanian Dr. Brian G.M. Durie Dr. Kenneth C. Anderson Dr. Robert Vescio and Dr. Robert A. Kyle
12.01.00

WAM 2000 Faculty:

  • Dr. Morie Gertz
  • Dr. Bart Barlogie
  • Dr. James R. Berenson
  • Dr. Raymond Alexanian
  • Dr. Brian G.M. Durie
  • Dr. Kenneth C. Anderson
  • Dr. Robert Vescio
  • Dr. Robert A. Kyle

In September, the International Myeloma Foundation hosted WAM 2000, a clinical conference for physicians on Waldenstroms, amyloidosis and myeloma. The program was designed to meet the educational needs of hematologists and oncologists who care for patients with multiple myeloma, Waldenstroms andamyloidosis.

The conference aimed to provide a topical overview of the diagnostic, management and research efforts surrounding the three disease areas. In working with the Institute for Continuing Healthcare Education, the IMF was able to offer participants upto eight hours of category 1 credit toward the AMA Physician’s Recognition Award.

The goal of WAM 2000 was to ensure that, by the end of the conference, attendees would be able to:

  • Discuss new diagnostic and prognostic techniques that may improve the baseline evaluation of patients;
  • Summarize the latest information about front line treatments;
  • Discuss alternative approaches to treatment for patients who fail to respond to standard therapy, and;
  • Review current support care measures to ensure maximum opportunity for improvement in the quality of life for patients.

An interactive format throughout the conference allowed several opportunities for WAMs 75 participants to ask questions. In addition, a Meet the Professor session was held and participants were encouraged to bring with them one or two case histories for discussion and review with the conference’s expert faculty.
WAM 2000 is just one example of the IMF’s varied patient and physician education and support programs. For information on upcoming patient and physician programs, stay tuned to Myeloma Today, or visit the IMF website at www.myeloma.org.


 related articles